OrbiMed
Edit

OrbiMed

http://www.orbimed.com
Last activity: 17.08.2026
Active
Invests in categories: BioTechCareDevelopmentDrugHealthcareHealthTechMedTechPlatformProductTechnology
OrbiMed is a leading healthcare investment firm that invests in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. It has over $18 billion in assets under management and operates globally across North America, Asia, and Europe.

OrbiMed’s investment strategy is to identify and support innovative companies that can improve the lives of patients and create value for investors. It invests across all stages of development, from seed to growth to late-stage. It also provides non-dilutive structured debt capital and royalty monetization to commercial-stage healthcare companies.

OrbiMed’s investment criteria vary depending on the sector, stage, and geography of the opportunity. However, some common factors that OrbiMed looks for are:

A strong management team with relevant expertise and track record.
A differentiated product or service with a clear competitive advantage and market potential.
A compelling scientific rationale and clinical evidence for the product or service.
A favorable regulatory and reimbursement environment.
A reasonable valuation and attractive return potential.
OrbiMed’s portfolio includes over 200 companies across various therapeutic areas, modalities, and geographies. Some of its notable portfolio companies are:

ADARx Therapeutics, a biotechnology company developing messenger RNA targeting therapeutics.
Biohaven Pharmaceuticals, a biopharmaceutical company focused on neurological diseases.
Inari Medical, a medical device company specialized in venous disease.
Twist Bioscience, a synthetic biology company that provides DNA writing and data storage solutions.
OrbiMed’s benefits for its portfolio companies include:

Access to a large and experienced team of investment professionals with diverse backgrounds and expertise in healthcare.
Access to a global network of industry contacts, partners, and advisors.
Access to capital across multiple funds and strategies.
Active involvement and guidance in strategic, operational, and financial matters.
Long-term commitment and support for growth and value creation.
News
4.2K
Portfolio
253
Persons
27
Mentions
354
Location: United States, New York
Employees: 51-200
Founded date: 1989
Investment Stage: Seed; Series A; Series B; Series C; Series D; Grant; Private Equity

Portfolio 253

DateNameWebsiteTotal RaisedLocation
17.08.2026Leal Thera...lealtx.com$75MUnited Sta...
16.07.2026TytoCaretytocare.com$303.5MUnited Sta...
08.07.2026Fore Biofore.bio$180.4MUnited Sta...
19.05.2026Accro Bios...accropeutics.com$62MChina
06.05.2026Windward B...windwardbio.com$565MSwitzerlan...
07.04.2026SpectronRxspectronrx.com$85MUnited Sta...
02.04.2026StairMedstairmed.com$500M-
26.03.2026Pinnacle M...pinnaclemedicines.com$89MUnited Sta...
23.01.2026Mendramendra.com$82M-
16.01.2026Sukino Hea...sukino.com$69.05MUnited Sta...
Show more

Persons 27

DateFirst NameLast NameTitleLinkedInLocation
-DanielYingExecutive ...linkedin.c...-
-PriyaMalebennurDirector, ...-
-JiWangExecutive ...linkedin.c...-
-NatashaShervaniVice Presi...linkedin.c...-
-JonathanLeePartnerlinkedin.c...-
-DimitriKrainc, M....Venture Pa...-
-AndrewFinebergManaging D...linkedin.c...-
-DonnieMcGrath, M...Venture Pa...linkedin.c...-
-MattXieVice Presi...-
-LeoMaSenior Ass...linkedin.c...-
Show more

News 4197

DateTitleDescription
16.11.2023Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer-
10.11.2023Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ-
07.11.2023Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration-
06.11.2023Frontera Therapeutics announces CDE clearance to initiate clinical trial of a First-in-class gene therapy for the treatment of RPGR-associated X-linked Retinitis Pigmentosa-
03.11.2023Aerin Medical Announces Advances for Chronic Rhinitis Treatment with New CPT Code and Final CMS-Established Payment Rates-
02.11.2023CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition-
02.11.2023Terremoto Biosciences Closes $175 Million Series B Financing-
02.11.2023Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023-
01.11.2023InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23-
01.11.2023SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting-
Show more

Mentions in press and media 354

DateTitleDescription
17.08.2026Leal Therapeutics Raises $30M in Second Close of Series A FundingLeal Therapeutics, a Worcester, MA-based provider of neuro-metabolic therapeutics for central nervous system disorders, raised $30M in the second close of its Series A funding. Backers included Eli Lilly and Company, OrbiMed, Newpath Partne...
30.07.2026ADQ-anchored Lunate, Orbimed, Creaegis invest in Indian healthcare firmPremium Credit: Freepik A host of domestic and foreign institutional investors including private equity firms and pension funds are betting on a...... This is a Premium article. Please subscribe or log in to read the full story! Here's a se...
18.07.2026TytoCare Bolsters Leadership, Secures $25M+ for AI-First Chronic CareTytoCare secures over $25 million in growth financing. Adam Pellegrini joins as CEO. Greg Orr becomes COO. This investment fuels a major strategic pivot. TytoCare now targets high-acuity chronic conditions. Its FDA-cleared handheld device c...
17.07.2026Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc.Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. Fri, Jul 17, 2026 08:00 CET Report this content 17 July 2026 THE BIOTECH GROWTH TRUST PLC (“BIOG” or the "Company") Eli Lilly to acquire BIOG portfolio company, AtaiBec...
16.07.2026TytoCare Secures $25M and Appoints Adam Pellegrini as CEOAdam Pellegrini, CEO at TytoCare What You Should Know Telehealth innovator TytoCare has announced a $25 million-plus growth financing round alongside the high-profile appointment of digital health veteran Adam Pellegrini as Chief Executive ...
15.07.2026TytoCare Names Adam Pellegrini As CEO And Closes $25+ Million Growth Round To Scale AI-First Clinical Enablement PlatformTytoCare, pioneer of remote physical examination technology featuring FDA-cleared medical devices, announced the appointment of Adam Pellegrini as Chief Executive Officer alongside the closing of a $25 million-plus growth round led by Insig...
14.07.2026FORE Biotherapeutics Inks $67.4 Million Series D-2 Extension PHILADELPHIA, PA, FORE Biotherapeutics, a company dedicated to developing targeted therapies to treat patients with cancer, announced the closing of an upsized Series D-2 extension financing of $67.4 million. >> Click here for more f...
13.07.2026Indian startups raised over $131 million from July 06 to July 11, 2026; Iswarya tops the listBetween July 6 to July 11, 2026, as many as 21 Indian startups from diverse sectors raised over $132.11 million in funding from investors. That is 5% up week-on-week from $125.72 million logged the previous week, when Limelight Diamonds rai...
11.07.2026FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer DrugFORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor...
10.07.2026FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance PlixorafenibFORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In